Vascular dysfunction – the disregarded partner of Alzheimer’s disease

Commentary on the “NIA-AA Research Framework: Towards a Biological Definition of Alzheimer’s Disease” and the need to include biomarkers of vascular dysfunction

The recent 2018 NIA-AA [National Institute on Aging, NIA; Alzheimer’s Association, AA] Research Framework “Towards a Biological Definition of Alzheimer’s Disease” (referred to below as the Research Framework) outlines a biomarker system to classify individuals in the Alzheimer’s disease (AD) continuum using imaging biomarkers and cerebrospinal fluid (CSF) biomarkers focused on amyloid-β (Aβ) [A], tau [T], and neurodegeneration [(N)] – the “AT(N)” biomarker system [1]. The AT(N) system has been proposed to define a biomarker-based approach to diagnose AD for research observational and interventional studies, but at the same time does not imply a specific order of events nor causality and acknowledges an uncertain relationship between the A and T biomarkers and disease symptoms [1]. The Research Framework defines an individual with biomarker evidence of both Aβ deposition and pathologic tau as having AD, yet acknowledges that amyloid and tau deposits may not be causal to AD [1]. The Research Framework distinguishes between AD which is reserved for the pathologic entity (defined by amyloid and tau biomarkers) and the Alzheimer’s clinical syndrome. As Alzheimer’s clinical syndrome has been shown to be a disease with mixed pathologies, and AD may also be multifactorial, other factors as illustrated in Figure 1 will likely contribute to and/or modify onset and progression of symptoms, as discussed more in sections below. Below we use the term AD (not strictly defined as amyloid+ and tau+ biomarkers), but rather more broadly inclusive of AD as a multifactorial and heterogenous disease.

Despite the substantial evidence indicating early vascular contributions to AD pathophysiology and dementia, vascular disease very commonly accompanies AD and may also be in causal pathway. Below, we first briefly discuss evidence that vascular dysfunction is a prominent and early feature in prodromal AD, and, without implying a causality, order of events, or specificity, suggest that adding vascular biomarkers to the proposed AT(N) biomarker system will help to better characterize and understand contributions of vascular dysfunction to cognitive impairment in patients suffering from AD. Next, we focus on 18F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET), a molecular imaging biomarker for early preclinical AD and mild cognitive impairment (MCI) mentioned in the AT(N), and examine the evidence indicating that FDG-PET should also be considered a biomarker of vascular and/or blood-brain barrier (BBB) transport dysfunction rather than uniquely neuronal hypometabolism and neurodegeneration, as elaborated in recent reviews [2,3]. Recognizing these concepts will achieve a more balanced view of AD pathophysiology and its multifactorial origin and provide even better tools for early diagnosis of AD as well as pave the way for novel therapeutic approaches.

Vascular dysfunction and vascular biomarkers in AD. Neuropathological studies have shown that cerebrovascular pathology is a major risk factor for clinically diagnosed AD-type dementia with clinical expression associated with low scores in most cognitive domains [4]. A large autopsy-based neuropathological study importantly revealed that 80% of patients diagnosed with AD and no evidence of mixed (vascular) dementia, had vascular pathology including cortical infarcts, lacunes, cerebral microbleeds and multiple microinfarcts indicative of small vessel disease (SVD), intracranial atherosclerosis, arteriolesclerosis, perivascular spacing and cerebral amyloid angiopathy (CAA) [5], supporting the concept that cerebrovascular dysfunction is prominent in AD and lowers the threshold for dementia for a given AD pathology burden. Further, mounting evidence shows that vascular risk factors (VRFs) are associated with lower FDG-PET [6], cerebrovascular disease as expected [7], higher
cerebral Aβ burden [6,8], higher tau burden [9], and act synergistically with Aβ burden to promote cognitive decline [10]. Structural arterial changes leading to functional changes in cerebral blood flow (CBF) [11] are associated with the rate of accumulation of cerebral Aβ over time [12] and the overlap of cerebrovascular and cerebral Aβ pathologies in older adults [13]. The overlap of cerebrovascular and traditional AD pathologies is not exclusive to the late onset form of AD but also present in autosomal dominant AD (ADAD) [14]. It is important to extend epidemiology research beyond clinical VRFs to subclinical vascular measures that point to the mechanistic pathways linking vascular dysfunction to the various aspects of AD and dementia pathology in diverse cohorts.

Vascular dysfunction appears early in AD, as shown using different imaging biomarkers of BBB integrity [15–20], brain microbleeds [20–25], cerebrovascular reactivity [20,26,27], resting CBF [28–40,17,20,41], and increased cerebrovascular resistance [42]. BBB permeability to gadolinium, measured by dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI), is routinely used for clinical diagnosis of multiple sclerosis, stroke and brain tumors [43,44]. Only recently has the DCE-MRI technique been modified and advanced to detect subtle changes in BBB permeability in the living human brain with a sub-regional spatial resolution capable of detecting changes at the level of hippocampal subfields and different gray and white matter regions studied in parallel [15,19,20,45]. Early BBB breakdown has been shown in the hippocampus and its CA1 and dentate gyrus sub-regions in individuals with MCI [15], and in several gray and white matter regions in early stages of AD [16–18]. Additionally, BBB failure was found to be a core mechanism in cerebral SVD and dementia (see below) [45].

Widespread utilization of various imaging sequences could be easily implemented to evaluate different types of vascular dysfunction in AD pathophysiology. FLAIR [fluid-attenuated inversion recovery] is the most common sequence used in aging and AD studies to define macrostructural white matter hyperintensities (WMH). Microstructural changes at tissue level interstitial fluid (ISF) shifts are easily detected on diffusion tensor imaging (DTI) sequences and quantified using the mean diffusivity parameter, which several studies have shown is highly sensitive to white matter microstructural damage and correlates with BBB failure [46,47]. Another vascular biomarker, microbleeds, can be measured with short 5 min T2*-weighted sequences [20–25]; this would be easy to add to existing AD MRI protocols. Cerebral microbleeds are related to vascular wall damage by arteriosclerosis or CAA, and also reflects a marker of ischemic white matter disease [3]. Additionally, the DCE sequence to evaluate subtle, sub-regional BBB permeability lasts about 15 minutes, requires intravenous injection of a gadolinium contrast agent, and can be obtained in either coronal or transverse orientations for individual input function analysis. The DCE sequence has already been added to imaging protocols at several Alzheimer’s Disease Centers (ADC) including University of Southern California (USC), Washington University in St. Louis, and Banner Alzheimer’s Institute, and is also being used to study individuals with ADAD at USC in addition to its frequent use in patients with SVD (sporadic and genetic) andBinswanger’s type of dementia. Functional changes such as impaired cerebrovascular reactivity that reflects diminished vasodilation of cerebral vessels in response to a CO2 inhalation challenge can be measured using either blood oxygenation level dependent (BOLD) functional MRI [48,49] or arterial spin labeling (ASL) [26] at the tissue level, or transcranial Doppler (TCD) [27]. CBF reductions are detected by several different imaging methods, including pseudo-continuous ASL-MRI [17,28,33–37,50,41,51,52], 4-dimensional phase contrast angiography [53], dynamic susceptibility-contrast (DSC) MRI [38], single-photon emission-computed tomography (SPECT) [30–32,54], TCD [55], perfusion computed tomography (CT) [56], and [15O]-PET [29]. Recently, using advanced DSC methods it is now possible to specifically detect capillary dysfunction which is impaired in AD [57].

Beyond the recognized microvascular dysfunction, emerging evidence also indicates CBF reductions at large and medium sized arteries in adults at risk for AD [52] and in AD models [58], supporting that quantification of vascular changes at all levels of the intracranial vasculature may
provide a more comprehensive and possibly more sensitive marker for detecting early AD changes. New methods of evaluating angiography of 3-dimensional vascular anatomy using time-of-flight (TOF) MRI sequences can provide several quantitative parameters such as number and order of branches, branch artery lengths and volumes, tortuosity, planarity, intensity etc. can be derived [59]. Already used clinically to evaluate vascular stenosis, detect aneurysms and vascular disease, TOF sequences could easily be added to MRI protocols and applied to cognitively normal older adults, MCI and AD for comprehensive analysis of angiographic data with the potential to provide new insights into vascular contributions to AD.

In addition to imaging biomarkers, CSF and blood-based biomarkers of vascular damage in the AD continuum are emerging such as, for example, CSF soluble platelet-derived growth factor receptor-β (sPDGFRβ) reflecting mural cell injury [15,60] and CSF fibrinogen and standard albumin CSF/plasma quotient reflecting BBB breakdown [15,61,62]. Biofluid (CSF and blood) biomarkers of vascular damage should continue to be validated by multiple independent studies. Furthermore, the more conventional pattern of low Aβ42 in the CSF reflect a failure of drainage of Aβ from the ISF of the brain across blood vessels and by perivascular ISF flow [63,64].

Moreover, imaging biomarkers of SVD are already established, well-characterized and easy to recognize, including WMH, lacunes (subcortical infarcts of vascular origin), microbleeds, etc., as well as more subtle markers now emerging (such as microinfarcts and perivascular spaces, PVS) [19,63]. Beyond the vascular imaging biomarkers defined above, further inclusion of SVD features in the differential biological approach in sporadic AD, ADAD [65] and other dementias would be relatively easy to achieve and is highly relevant since SVD of the brain contributes to > 50% of all dementias worldwide including AD [19,66–69]. Neuroimaging techniques already used in SVD and vascular dementia should similarly be applied to AD and other dementias [70]. Acknowledging and further characterizing vascular contributions to the AD and association with biomarker-based AD pathology is important for ongoing observational studies in diverse cohorts and to target interventional strategies to prevent or slow cognitive decline and dementia. This may be particularly important in under-represented minority groups including African-Americans and Latinos at greater risk for cardiovascular disease (CVD), cerebrovascular disease and AD.

FDG-PET. 18F-fluoro-2-deoxy-D-glucose (FDG), a radio-labeled form of 2-deoxy-D-glucose (2DG), which is an analog of glucose, is frequently used as a ligand for FDG-PET studies as an “surrogate” marker for glucose brain uptake [20]. Impaired FDG-PET uptake is often considered an exclusive biomarker of brain hypometabolism or neurodegeneration as proposed in the NIA-AA Research Framework [1]. However, below we examine evidence that FDG also tracks BBB transport of glucose, and therefore low FDG-PET uptake should also be considered as a biomarker of vascular dysfunction.

Glucose and its 2DG and FDG analogs are transported across the BBB via brain endothelial-specific glucose transporter-1 (GLUT1), and then taken up by different cell types (e.g., neurons) in the brain via their respective glucose transporters, which does not include GLUT1 [71–73]. The ubiquitous intracellular hexokinase then phosphorylates glucose, 2DG and FDG to their respective 6-phosphates (6P) [74–77]. However, after this initial phosphorylation step by hexokinase there are critical differences between glucose vs. 2DG/FDG metabolic fates in brain [71,74–77] as illustrated in Figure 2. After phosphorylation, glucose-6P is converted to fructose-6P that undergoes glycolysis followed by pyruvate entry into the Krebs cycle and oxidative phosphorylation. But, glucose analogs 2DG and FDG are not substrates for glucose-6P isomerase, and thus cannot be converted into fructose-6P, which is the necessary step to enter the glycolytic pathway as well as the subsequent Krebs cycle [74–77]. Instead, 2DG-6P and FDG-6P remain trapped in the brain in their 6P forms, and are only slowly eliminated from the brain [74–77], as has been shown by multiple independent studies. For example,
showed mixed results including a diminished hexokinase activity significantly advance on how to prevent and treat vascular disease and on interventions trials. TCD, bio Incorporate metabolized should be used by future studies to specifically determine the role of glucose transport in phosphorylation metabolism functions of neurons and non-studies, and does not generate a single step into [93,101] in AD brains reported rather conflicting results BBB post reductions in glucose hypometabolism, [74,79,80] 2DG-6P remains trapped in brain cells [78,81] and is slowly eliminated from the brain.

Importantly, FDG-PET studies show diminished glucose uptake in several brain regions (e.g., precuneus, posterior cingulate, right angular gyrus, bilateral temporal cortices) prior to any detectable neurodegenerative changes, brain atrophy and/or conversion to AD [82]. Reduced regional FDG brain uptake in AD is not due to brain atrophy, as confirmed by studies in the posterior cingulate gyrus and parieto-temporal cortex [83]. Longitudinal FDG-PET findings have suggested that reductions in hippocampal glucose uptake during normal aging can predict cognitive decline years in advance of clinical AD diagnosis [84]. Diminished glucose uptake in the hippocampus, parieto-temporal cortex and/or posterior cingulate cortex has been repeatedly shown by FDG-PET in early AD [85], and also in individuals at genetic risk for AD [86,87], with a positive family history of AD [88], and/or MCI or no cognitive impairment prior to progression to AD [89]. The patterns of FDG brain uptake can also discriminate individuals with normal cognition from MCI and AD patients [85], suggesting region-specific insufficiency in brain delivery and uptake of glucose to the brain. FDG-PET changes preceding neurodegeneration are not only found in humans [82–84,90], but also in transgenic AD models [91].

Although FDG-PET changes in AD are typically interpreted as the result of neuronal glucose hypometabolism, in vivo dynamic FDG-PET kinetic studies in humans consistently show significant reductions in glucose BBB transport in AD subjects compared to controls [92–95], consistent with post-mortem studies showing significantly reduced GLUT1 levels in brain capillaries, a site of the BBB in vivo [96–99]. On the other hand, a few studies that directly measured hexokinase activity levels in AD brains reported rather conflicting results showing a decrease [92,94], increase [100] or no change [93,101]. Additionally, in contrast to glucose, 2DG does not proceed beyond the initial phosphorylation step into glycolytic or Krebs metabolic pathways as shown by rodent [74–78] and human [92–95] studies, and does not generate a single high energy adenosine-3-phosphate (ATP) molecule to maintain functions of neurons and non-neuronal cells in brain. The lack of FDG contribution to brain energy metabolism supports the concept that FDG-PET tracks BBB transport of glucose and an initial phosphorylation step by hexokinase, but it does not dependably track all steps involved in energy metabolism of glucose in neurons and is not metabolized by neurons. New tracers such as 3-O-[14C]-methyl-glucose that exclusively track BBB transport and are not phosphorylated by hexokinase or metabolized should be used by future studies to specifically determine the role of glucose transport in AD as possibly an early biomarker [102].

Recommendations. We recommend the following extensions of the Research Framework. (1) Incorporate biomarkers of vascular dysfunction to assess vascular contributions to AD using imaging biomarkers such as FLAIR, DTI, T2*-weighted sequences, DCE, ASL, and DSC MRI sequences, TCD, BOLD-fMRI, and TOF, and molecular biomarkers of vascular damage in individuals with AD or dementia risk or with suspected dementia; whenever and whichever possible, vascular imaging biomarkers should be adopted in AD research studies, large epidemiological studies and interventional trials [103]. Integration of vascular dysfunction biomarkers into the diagnostic process may allow for earlier diagnosis of AD in some patient subsets. Recognizing and including the wealth of knowledge on how to prevent and treat vascular disease and on interventions to modify vascular dysfunction could significantly advance research in AD and dementia, thus ultimately helping patients. (2) Reclassify diminished FDG brain uptake by PET not as a unique biomarker of neuronal hypometabolism due to diminished hexokinase activity, but also as a biomarker tracking vascular, i.e. BBB transport, abnormality. This particularly, as a few direct studies determining hexokinase activity in AD subjects showed mixed results including a decrease [92,94], increase [100] or no change [93,101], suggesting
that equating diminished FDG-PET uptake with cellular hypometabolism should not be made unless both transport and phosphorylation components are measured simultaneously by FDG-PET kinetic studies, which should show directly whether metabolism is affected or not, but unfortunately has not been done in most FDG-PET studies. This reclassification could have profound consequences for the diagnosis and treatment of AD patients because it would highlight the potential of FDG uptake to identify therapeutic windows of opportunity prior to the onset of irreversible neurodegeneration.

Recent evidence indicates that reducing stroke incidence also reduces dementia incidence [69,104]. Later this year (October 2018), a one day satellite meeting held by the World Health Summit will jointly discuss cerebrovascular and neurodegeneration diseases and the concept of dementia prevention by stroke prevention: https://www.worldhealthsummit.org/satellites/dementia-stroke-prevention.html. Similarly, managing and reducing VRFs may protect against cognitive decline, since VRFs act synergistically with Aβ to promote cognitive decline [10]. VRF reduction approaches may be particularly effective in ethnic minorities at greater risk for CVD, cerebrovascular disease and AD. Remarkably, a third of elderly individuals have considerable Alzheimer-type pathology (plaques and tangles) in brain but no cognitive impairment [105]. We are only beginning to understand some of the potential mechanisms of brain resistance and brain resilience [106]; just as biomarkers of disease are important, so are biomarkers of resilience. Finally, future longitudinal studies in individuals at genetic risk for AD should examine how changes in vascular biomarkers relate to amyloid and tau biomarker changes, structural and functional brain connectivity, and cognitive measures over time.

The 2018 Research Framework attempts to unify language of biomarker-based definition of AD, but it underrecognizes AD as a heterogeneous disease and does not clearly define AD in the context of multifactorial and functional systems contributing to disease pathophysiology. Many factors can influence onset and progression of cognitive dysfunction in AD, which besides aging, includes genetics, VRFs, environmental factors, microbiome, and lifestyle, to mention a few (see Figure 1). All these factors influence aging of the vascular system, innate immunity and neuronal health and function directly independent of amyloid and tau, as well as synergistically with Aβ and tau (see Figure 1). The Research Framework acknowledges vascular biomarkers could be added when they are defined, but unfortunately does not fully appreciate that several vascular biomarkers “ready-to-be-used” already exist and are well defined. Since amyloid and tau deposits may not be causal in AD pathogenesis, as recognized by the Research Framework [1], it is the right time to encourage inclusion of biomarkers of vascular dysfunction in observational and interventional research studies. Finally, rather than focusing only on amyloid and tau, broadening the perspective and study of contributing factors to AD will aid in patient-directed therapeutic efforts to apply the right drug(s) - at the right dose - at the right time - in the right study design - and with the right outcome measures for successful intervention to delay, prevent and/or reverse dementia and AD. Individualized, targeted therapies for AD patients will be successful when the complexity of AD pathophysiology is fully appreciated so that multidisciplinary team efforts can be mounted to successfully address one of the most challenging diseases in the 21st century.

Acknowledgements
Supported by the National Institutes of Health (NIH) grants R01AG023084 (B.V.Z.), R01NS090904 (B.V.Z.), R01NS034467 (B.V.Z.), R01AG039452 (B.V.Z.), R01NS100459 (B.V.Z.), 5P01AG052350 (B.V.Z.), 5P50AG005142 (H.C.C.; University of Southern California Alzheimer’s Disease Research Center), EB015922 (A.W.T.; Laboratory of Neuro Imaging, LONI), R37-NS089323 (C.I.), R01-NS100447 (C.I.), R01-NS09544 (C.I.), R01-NS/HL037853 (C.I.), R01-NS034179 (C.I.), KL2-TR002002 (S.E.L.), R01-AG064248 (H.M.G.), RF1-AG054548 (H.M.G.), P30-AG005131 (H.M.G.), R21-AG056952 (H.M.G.), P30AG049638 (T.M.H.; S.N.L.), R01AG054069 (T.M.H.; S.N.L.), R01HL096814 (T.M.H.), R01AG053938 (T.M.H.) in addition to the Alzheimer’s
Association, Cure Alzheimer’s Fund, and the Foundation Leducq Transatlantic Network of Excellence for the Study of Perivascular Spaces in Small Vessel Disease reference no. 16 CVD 05.

Commentary Prepared By:

¹Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
²Department of Psychology, University of Southern California, Los Angeles, CA, USA.
³Alzheimer's Disease Research Center, Keck School of Medicine at the University of Southern California, Los Angeles, CA, USA.
⁴Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
⁵Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
⁶Huntington Medical Research Institutes, Pasadena, CA, USA.
⁷Laboratory of Neuro Imaging (LONI), Stevens Institute for Neuroimaging and Informatics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
⁸Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
⁹Neuroimaging Sciences and Brain Research Imaging Center, Division of Neuroimaging Sciences, Center for Clinical Brain Sciences, UK Dementia Research Institute at the University of Edinburgh, UK.
¹⁰LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Heart and Stroke Foundation Canadian Partnership for Stroke Recovery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
Department of Medicine (Neurology), Hurvitz Brain Sciences Program, Canadian Partnership for Stroke Recovery, and LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, and Toronto Dementia Research Alliance, University of Toronto, Toronto, Toronto, Canada.

Section for Translational Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Division of Glia Disease and Therapeutics, Center for Translational Neuromedicine, University of Rochester Medical School, Rochester, NY, USA.

Department of Anesthesiology, Yale School of Medicine, New Haven, CT, USA.

Institute for Stroke and Dementia Research (ISD), Ludwig-Maximilians-University Munich, Munich, Germany.

Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.

Institute of Clinical Neurosciences, University of Bristol, School of Medicine, Level 2 Learning and Research, Southmead Hospital, Bristol, UK.

Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, City Hospital Campus, Nottingham, UK; Stroke, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, UK.

Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.

Neurovascular Research Group, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.

Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology and the National Hospital for Neurology and Neurosurgery, London, UK.

Faculty of Medicine, University of Southampton, Southampton, UK.

British Heart Foundation, Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK.

Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

Stroke and Neurovascular Regulation Laboratory, Departments of Radiology and Neurology Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.

Department of Anesthesiology and Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.

Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL 60612, USA.

Department of Anesthesiology, Department of Pharmacology, University of Illinois at Chicago, Chicago, IL 60612, USA.

Department of Pharmacology, Department of Medicine, The Center for Lung and Vascular Biology, The University of Illinois College of Medicine, Chicago, IL, USA.
Department of Pharmacology, University of Arizona, Tucson, Arizona, USA.

Department of Pathology and Laboratory Medicine, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.

Department of Neurosciences, University of California, San Diego, CA, USA.

Department of Radiology, University of Washington, Seattle, WA, USA.

Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Alzheimer’s Disease Research Center, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Departments of Pharmacology and Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Memory Aging and Cognition Centre, National University Health System, Singapore.

Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales Australia, Sydney, Australia.

Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, UK.

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.

“L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.

Department of Neurology, State University of New York-Downstate Medical Center, Brooklyn, NY, USA.

Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands.

Institute of Neuroscience and Physiology, University of Gothenburg, Gothenberg, Sweden.

Hotchkiss Brain Institute, University of Calgary, Alberta, Canada.

Department of Medicine and Therapeutics, Therese Pei Fong Chow Research Centre for Prevention of Dementia, The Chinese University of Hong Kong, Hong Kong SAR, China.

Gerald Choa Neuroscience Centre, Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.

School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.

Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands.

Institutes of Neurology and Healthcare Engineering, University College London, London, UK.

Section of Geriatrics, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.

Department of Population Health Sciences, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; Institute for Medical Biometry, Informatics and Epidemiology (IMBIE), Faculty of Medicine, University of Bonn, Bonn, Germany.

Department of Neurology, Methodist Neurological Institute, Houston, TX, USA.

Laboratory of Cerebrovascular Research, Montreal Neurological Institute, McGill University, Montréal, QC H3A 2B4, Canada.
9

The Framingham Heart Study, Framingham, MA, USA; Department of Neurology, Boston University School of Medicine, Boston, MA, USA.

56Departments of Neurology and Epidemiology, Johns Hopkins University, Baltimore, MD, USA.

Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands

Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.

59Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.

Laboratory of Cerebral Vascular Biology, Department of Biomedical Sciences, University of Minnesota Medical School Duluth, Duluth, MN 55812, USA.

Division of Neurology, Department of Clinical Neurological Sciences, Western University, London, Ontario, Canada.

62Leonard Davis School of Gerontology, Dornsife College, University of Southern California, Los Angeles, CA, USA.

‡ Co-sharing senior authors

Address correspondence:

Berislav V. Zlokovic, M.D., Ph.D.
Zilkha Neurogenetic Institute
1501 San Pablo Street
Los Angeles, CA 90089
Phone: 323.442.2722 / Fax: 323.666.2184
Email: zlokovic@usc.edu
References


Alzheimer’s disease is a multifactorial and heterogeneous disease. Alzheimer’s disease (AD) is defined as a unique neurodegenerative disease based on the presence of amyloid-β (Aβ) and tau deposits. Additional factors (red), however, contribute to the onset and progression of AD pathophysiological changes directly affecting brain vascular system (i.e., blood-brain barrier leakages, blood flow shortfalls) and innate immune system, and neuronal health and functioning independently and/or simultaneously with Aβ and tau pathologies. This includes, but is not limited to: genetic risk factors, vascular factors, environmental factors including socioeconomic stress, microbiome, and lifestyle. Aging still remains the key risk factor for AD, and also profoundly affects brain vasculature, innate immune responses and neuronal functions (blue).
Figure 2. Schematic illustrating key differences in brain metabolic fate of glucose and its non-metabolizable surrogate analog 2-deoxy-D-glucose (2DG) and its radiolabeled form $^{18}$F-fluoro-2-deoxy-D-glucose (FDG). Glucose, a key energy metabolite in the brain, is transported across the blood-brain barrier (BBB) via endothelial-specific glucose transporter-1 (GLUT1) hexose transporter. After uptake by brain cells, glucose undergoes glycolysis followed by Krebs cycle and oxidative metabolism providing the fuel for physiological brain functions through the generation of high-energy adenosine-3 phosphate (ATP) molecules, the foundation for neuronal and non-neuronal cell maintenance and the generation of neurotransmitters. On the other hand, glucose surrogate analogs 2DG and FDG, although still transported across the BBB via GLUT1 hexose transporter, cannot enter the glycolytic pathway or Krebs cycle in brain. After the initial hexokinase step, 2DG-6P and FDG-6P get trapped in the brain, because they are not substrates for glucose-6P isomerase, which is a necessary metabolic step in the glycolytic pathway. Therefore, 2DG and FDG are not metabolized by the glycolytic pathway or Krebs cycle, do not generate any ATP energy-donor molecules in brain, and their net metabolic rate in brain is zero joules.